---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-030396"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T20:51:37.361188+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neumora modifies KOASTAL-2/-3 MDD studies, delays data to 2026; R&D head departs

## Summary
- KOASTAL-2/-3 paused, resume March 2025; topline data from KOASTAL-3 in Q1 2026 and -2 in Q2 2026.
- Phase 2 bipolar depression trial for navacaprant discontinued to prioritize KOASTAL program.
- Robert Lenz, M.D., Ph.D., head of R&D, leaving company; will serve in advisory role.
- Cash, cash equivalents and marketable securities $307.6M as of Dec 31, 2024, funding into mid-2026.
- Q4 2024 net loss $58.8M vs $108.7M Q4 2023; full year net loss $243.8M vs $235.9M.

## SEC filing metadata
- accession: 0000950170-25-030396
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000095017025030396/0000950170-25-030396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000095017025030396/nmra-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-030396
- JSON: https://secwatch.observer/filing/0000950170-25-030396.json
- Plain text: https://secwatch.observer/filing/0000950170-25-030396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.